Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

1713 - Phase I, Open-label, Dose-Finding Study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in Combination with Enzalutamide in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Date

10 Sep 2017

Session

Genitourinary tumours, prostate

Topics

Cytotoxic Therapy;  Clinical Research;  Prostate Cancer

Presenters

Pasquale Rescigno

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

P. Rescigno1, J. de Bono2, A. Aparicio3, S. Chowdhury4, P. Twardowski5, N. Dawson6, U. Vaishampayan7, A.J. Pantuck8, Y. Zhou9, D. Fecteau10, G. Ganji11, J. Tolson12, D.A. Smith13, J. Medina14, L. Yan10

Author affiliations

  • 1 Division Of Clinical Studies, Prostate Cancer Targeted Therapies, The Institute of Cancer Research and The Royal Marsden Hospital, SM2 5NG - Sutton/GB
  • 2 Division Of Clinical Studies, Prostate Cancer Targeted Therapy Group, Institute of Cancer Research Royal Marsden Hospital, SM2 5PT - Sutton/GB
  • 3 Department Of Genitourinary Medical Oncology, Division Of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston/US
  • 4 Medical Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 5 Department Of Medical Oncology And Experimental Therapeutics, City of Hope, 91010 - Duarte/US
  • 6 Prostate Cancer Research And Treatment Center, Georgetown Univerisity, Lombardi Comprehensive Cancer Center, Washington D.C./US
  • 7 Solid Tumor Oncology, Wayne State University, Karmanos Cancer Center, Detroit/US
  • 8 Department Of Urology, Ronald Reagan UCLA Medical Center, Los Angeles/US
  • 9 Oncology - Biostatistics, GlaxoSmithKline USA, PA 19426 - Collegeville/US
  • 10 Oncology - Clinical Development, GlaxoSmithKline USA, PA 19426 - Collegeville/US
  • 11 Biology, GlaxoSmithKline USA, King of Prussia/US
  • 12 Oncology - Clinical Development, GlaxoSmithKline, RTP/US
  • 13 Clinical Pharmacology, PAREXEL International, Durham/US
  • 14 Oncology, GlaxoSmithKline, Collegeville/US
More

Resources

Abstract 1713

Background

GSK2636771 is a potent, adenosine triphosphate (ATP) competitive, selective, oral inhibitor of the PI3Kβ isoform that inhibits the growth of phosphatase and tensin homolog (PTEN) deficient tumor cells in preclinical models. Resistance to the androgen receptor (AR) inhibitor enzalutamide (Xtandi®) may be mediated through upregulation of the PI3K pathway. Thus, GSK2636771 may enhance PTEN deleted prostate cancer cell kill.

Methods

Within 30-days of documented progression on enzalutamide, subjects with PTEN deficient mCRPC are enrolled and treated with enzalutamide plus GSK2636771 in either dose escalation (DE) or dose expansion (DX) phases. Treatment continues until progressive disease (PD), unacceptable toxicities, consent withdrawal, or death. The primary objective is to assess safety, tolerability and determine the recommended phase 2 dose of this treatment combination. Secondary objectives include evaluation of pharmacokinetics, pharmacodynamics, biomarkers, and clinical activity per PCWG2/RECIST 1.1. All subjects receive 160 mg enzalutamide once daily (QD) + GSK2636771 starting at 300mg QD using a standard 3 + 3 DE design with planned 100 mg incremental escalations or de-escalation.

Results

In this ongoing study, 23 subjects received this treatment combination; 7 at 300 mg, 16 at 200 mg. Most AEs were Grade 1 or 2, with diarrhea the most common treatment-related AE (9/23; [39%]). Dose-limiting toxicities (DLTs) included Grade 3 hypocalcemia and reversible Grade 3 acute renal failure at 300mg and Grade 3 rash at 200mg. PK parameters suggested no drug-drug interaction between enzalutamide and GSK2636771. Among 13 evaluable patients at 200mg, 1 had a radiological partial response, and 2 had maximum PSA reductions of > 50%. Five subjects have been treated for ≥6 months. DE of 300 mg and DX of 200 mg cohorts are ongoing.

Conclusions

Our preliminary data indicate that GSK2636771 in combination with enzalutamide is largely well tolerated and confirm the clinical relevance of PI3Kb inhibition in PTEN-deficient mCRPC. GSK funds this study.

Clinical trial identification

Protocol Number: 200331; NCT02215096; EudraCT No: 2013-005111-27

Legal entity responsible for the study

GlaxoSmithKline

Funding

GlaxoSmithKline

Disclosure

J. de Bono: Consulting or Advisory Role (Institution/Self) for the following companies: Astellas, AstraZeneca, Genentech, Genmab, GSK, Merck, Pfizer and Sanofi. Research support for the institution received from AstraZeneca, Genentech, GSK, Sanofi and Janssen. A. Aparicio: Self: GSK-Research/Advisor; Janssen/BMS/Sanofi-Research; Genzyme-Honorarium Family Member: Boston Scientfic/Biosense Webster-Research/Advisor/Speaker/Leadership/Travel; St. Jude-Advisor/Speaker/Honorarium/Leadership; Hansen Medical-Research; Two Patents. S. Chowdhury: Self: GSK: Advisor/Speaker/Honorarium Sanofi: Research/Advisor/Speaker Clovis/Astellas/Janssen: Advisor/Speaker Novartis: Speaker/Honorarium Bayer: Speaker Johnson and Johnson: Research. P. Twardowski: Self: Astellas, Medivation, Janssen: Speaker/Honorarium Genentech: Advisor/Speaker Bayer, Sanofi: Speaker Roche: Advisor Exelxis: Stock Shareholder. N. Dawson: Self: Genentech, Astellas, Eisai, Janssen, Amgen, Sanofi, Bayer, Novartis: Speakers’ bureau. Abbvie, AstraZeneca: Advisor Honorarium received for speakers bureau and advisory board. Y. Zhou: Full or part-time employment by GSK. D. Fecteau: GSK: Full or part-time employment and stock holder. G. Ganji, J. Tolson, J. Medina, L. Yan: GSK: Full or part-time employment and stock shareholder. D.A. Smith: PAREXEL International: Full or part-time employment. GSK: Stock shareholder. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.